736991-52-9

Basic information

• Product Name: 2-PIPERAZIN-1-YL-BENZALDEHYDE
• Synonyms: 2-PIPERAZIN-1-YL-BENZALDEHYDE;Benzaldehyde, 2-(1-piperazinyl)- (9CI);1-(2-Formylphenyl)piperazine
• CAS NO: 736991-52-9
• Molecular Formula: C₁₁H₁₄N₂O
• Molecular Weight: 190.24
• Product Categories: PIPERIDINE;API intermediates
• Mol File: 736991-52-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 355 °C at 760 mmHg
• Flash Point: 168.5 °C
• Appearance: /
• Density: 1.123 g/cm³
• Vapor Pressure: 3.23E-05mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.86±0.10(Predicted)
• CAS DataBase Reference: 2-PIPERAZIN-1-YL-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERAZIN-1-YL-BENZALDEHYDE(736991-52-9)
• EPA Substance Registry System: 2-PIPERAZIN-1-YL-BENZALDEHYDE(736991-52-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 736991-52-9(Hazardous Substances Data)

Usage

General Description

2-PIPERAZIN-1-YL-BENZALDEHYDE is a chemical compound consisting of a piperazine ring connected to a benzaldehyde group. It is commonly used as an intermediate in the synthesis of pharmaceutical and agrochemical products. 2-PIPERAZIN-1-YL-BENZALDEHYDE has been studied for its potential applications in the development of antipsychotic and analgesic drugs, as well as in the treatment of various medical conditions. It is also known for its antibacterial and antimicrobial properties. Additionally, 2-PIPERAZIN-1-YL-BENZALDEHYDE has been investigated for its potential use in the synthesis of novel materials and as a building block in organic chemistry. However, it is important to handle this compound with care due to its potential health hazards and toxicological effects.

InChI:InChI=1/C11H14N2O/c14-9-10-3-1-2-4-11(10)13-7-5-12-6-8-13/h1-4,9,12H,5-8H2

Upstream product

• 111373-03-6 2-(piperazin-1-yl)benzonitrile 
• 110-85-0 piperazine 
• 446-52-6 2-Fluorobenzaldehyde 
• 174855-57-3 tert-butyl 4-(2-formylphenyl)piperazinecarboxylate 

Downstream Products

• 748808-82-4 4-{(2R)-[(3R)-1,2,3,4-tetrahydroisoquinolinylcarboxamido]-3-(4-chlorophenyl)propionyl}-1-[2-formylphenyl]piperazine 
• 174855-57-3 tert-butyl 4-(2-formylphenyl)piperazinecarboxylate 
• 444583-08-8 4-{2-[(1-methyl-1H-imidazol-2-yl)-methylsulfanylthiocarboxyoxy-methyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 444582-62-1 1-N-tert-butoxycarbonyl-4-(2-(piperidin-1-ylmethyl)phenyl)piperazine 
• 668980-38-9 1-N-tert-butoxycarbonyl-4-(2-((dipropylamino)methyl)phenyl)piperazine 
• 444581-99-1 1-N-tert-butoxycarbonyl-4-(2-(pyrrolidin-1-ylmethyl)phenyl)piperazine 
• 444582-74-5 1-tert-butoxycarbonyl-4-{2-[hydroxy(1-methyl-1H-imidazol-2-yl)methyl]phenyl}piperazine 
• 444582-78-9 1-tert-butoxycarbonyl-4-[2-((1-methyl-1H-imidazol-2-yl)methyl)phenyl]piperazine 
• 444582-64-3 1-N-tert-butoxycarbonyl-4-(2-((diethylamino)methyl)phenyl)piperazine 

Relevant articles and documents

Aromatic-ring azacyclo derivatives and application thereof

Aromatic-ring azacyclo derivatives and an application thereof are provided. The invention relates to compounds represented by the formula (V), and a preparation method and an application thereof in medicines. In particular, the invention relates to derivatives of the compounds represented by the general formula (V), and a preparation method and the application thereof as therapeutic agents in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compounds disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, increase the expression of hepatic LDL receptors and inhibit the expression of PCSK9.

Structure-activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor

SAR studies on a series of piperazinebenzenes directed toward the human melanocortin-4 receptor resulted in potent MC4R agonists. Replacement of the triazole moiety of an initial lead 4 by a basic nitrogen baring a lipophilic side-chain increased the binding affinities of these compounds. Analogs bearing an additional hetero-atom in the side-chain possessed good agonist potency. Thus, 11h had a Ki of 11 nM, and 13g exhibited an EC50 of 3.8 nM and a Ki of 6.4 nM.

4-{(2R-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl} -1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist - Design, synthesis, and characterization

Recent studies have demonstrated that melanocortin-4 receptor (MC4R) antagonists can prevent weight loss in tumor-bearing mice, which indicates clinical usage for the treatment of cachexia. In our efforts to develop potent and selective antagonists of the human MC4R, we designed piperazinebenzylamines bearing a 2,4-dichlorophenylalanine, by utilizing information derived from structure-activity relationships of MC4R agonists and mutagenesis results of the MC4R and peptide ligands. On the basis of known MC4R agonists such 6, we successfully synthesized potent MC4R antagonists exemplified by 10, which possesses a Ki value of 1.8 nM in binding affinity. 10 does not stimulate cAMP release in HEK 293 cells expressing the human MC4 receptor at 10 μM concentration. It was demonstrated by Schild analysis that 10 was a competitive functional antagonist with a pA2 value of 7.9 in the inhibition of α-MSH-stimulated cAMP accumulation. 10 also penetrated into the brain when dosed intravenously in rats.